An FDA report describing clinical data for Epidiolex® in the treatment of LGS or Dravet syndrome highlighted alanine aminotransferase (ALT) levels were three times the normal limit in 13% of Epidiolex® treated patients. The gene discussed is GPT; the disease is Dravet syndrome.